Goldman Sachs’s Enanta Pharmaceuticals ENTA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $3.35M | Buy |
265,088
+46,272
| +21% | +$620K | ﹤0.01% | 4079 |
|
|
2025
Q4 | $3.45M | Buy |
218,816
+52,383
| +31% | +$665K | ﹤0.01% | 4102 |
|
|
2025
Q3 | $1.99M | Buy |
166,433
+50,298
| +43% | +$402K | ﹤0.01% | 4484 |
|
|
2025
Q2 | $878K | Sell |
116,135
-14,275
| -11% | -$85.9K | ﹤0.01% | 4794 |
|
|
2025
Q1 | $720K | Buy |
130,410
+6,549
| +5% | +$40.5K | ﹤0.01% | 4939 |
|
|
2024
Q4 | $712K | Sell |
123,861
-36,272
| -23% | -$348K | ﹤0.01% | 5044 |
|
|
2024
Q3 | $1.66M | Buy |
160,133
+75,322
| +89% | +$985K | ﹤0.01% | 4310 |
|
|
2024
Q2 | $1.1M | Sell |
84,811
-5,879
| -6% | -$79.4K | ﹤0.01% | 4364 |
|
|
2024
Q1 | $1.58M | Sell |
90,690
-95,951
| -51% | -$1.27M | ﹤0.01% | 4028 |
|
|
2023
Q4 | $1.76M | Sell |
186,641
-105,286
| -36% | -$981K | ﹤0.01% | 4025 |
|
|
2023
Q3 | $3.26M | Buy |
291,927
+52,858
| +22% | +$851K | ﹤0.01% | 3363 |
|
|
2023
Q2 | $5.12M | Buy |
239,069
+8,979
| +4% | +$265K | ﹤0.01% | 3093 |
|
|
2023
Q1 | $9.3M | Sell |
230,090
-5,356
| -2% | -$256K | ﹤0.01% | 2487 |
|
|
2022
Q4 | $11M | Buy |
235,446
+60,851
| +35% | +$2.77M | ﹤0.01% | 2501 |
|
|
2022
Q3 | $9.06M | Buy |
174,595
+36,239
| +26% | +$2.12M | ﹤0.01% | 2607 |
|
|
2022
Q2 | $6.54M | Buy |
138,356
+37,855
| +38% | +$2.05M | ﹤0.01% | 2890 |
|
|
2022
Q1 | $7.15M | Sell |
100,501
-19,150
| -16% | -$1.25M | ﹤0.01% | 3012 |
|
|
2021
Q4 | $8.95M | Buy |
119,651
+17,319
| +17% | +$1.36M | ﹤0.01% | 2876 |
|
|
2021
Q3 | $5.81M | Sell |
102,332
-41,099
| -29% | -$2.03M | ﹤0.01% | 3229 |
|
|
2021
Q2 | $6.31M | Buy |
143,431
+7,502
| +6% | +$367K | ﹤0.01% | 3129 |
|
|
2021
Q1 | $6.7M | Sell |
135,929
-25,485
| -16% | -$1.27M | ﹤0.01% | 2891 |
|
|
2020
Q4 | $6.79M | Sell |
161,414
-175,512
| -52% | -$7.72M | ﹤0.01% | 2768 |
|
|
2020
Q3 | $15.4M | Sell |
336,926
-26,822
| -7% | -$1.3M | ﹤0.01% | 1950 |
|
|
2020
Q2 | $18.3M | Sell |
363,748
-6,073
| -2% | -$314K | 0.01% | 1754 |
|
|
2020
Q1 | $19M | Buy |
369,821
+34,988
| +10% | +$1.86M | 0.01% | 1547 |
|
|
2019
Q4 | $20.7M | Buy |
334,833
+61,509
| +23% | +$3.81M | 0.01% | 1833 |
|
|
2019
Q3 | $16.4M | Buy |
273,324
+96,787
| +55% | +$7.19M | ﹤0.01% | 1940 |
|
|
2019
Q2 | $14.9M | Buy |
176,537
+32,473
| +23% | +$2.92M | ﹤0.01% | 2071 |
|
|
2019
Q1 | $13.8M | Sell |
144,064
-75,173
| -34% | -$6.74M | ﹤0.01% | 2174 |
|
|
2018
Q4 | $15.5M | Buy |
219,237
+61,638
| +39% | +$4.73M | ﹤0.01% | 2008 |
|
|
2018
Q3 | $13.5M | Buy |
157,599
+36,904
| +31% | +$3.7M | ﹤0.01% | 2224 |
|
|
2018
Q2 | $14M | Sell |
120,695
-38,513
| -24% | -$3.84M | ﹤0.01% | 2165 |
|
|
2018
Q1 | $12.9M | Buy |
159,208
+48,904
| +44% | +$3.76M | ﹤0.01% | 2153 |
|
|
2017
Q4 | $6.47M | Buy |
110,304
+26,269
| +31% | +$1.32M | ﹤0.01% | 2790 |
|
|
2017
Q3 | $3.93M | Buy |
84,035
+331
| +0.4% | +$13.3K | ﹤0.01% | 3380 |
|
|
2017
Q2 | $3.01M | Buy |
83,704
+25,154
| +43% | +$805K | ﹤0.01% | 3490 |
|
|
2017
Q1 | $1.8M | Sell |
58,550
-23,799
| -29% | -$741K | ﹤0.01% | 3850 |
|
|
2016
Q4 | $2.76M | Buy |
82,349
+61,136
| +288% | +$1.75M | ﹤0.01% | 3555 |
|
|
2016
Q3 | $564K | Buy |
+21,213
| New | +$493K | ﹤0.01% | 4935 |
|
|
2016
Q2 | – | Sell |
-7,923
| Closed | -$233K | – | 7066 |
|
|
2016
Q1 | $233K | Sell |
7,923
-11,668
| -60% | -$325K | ﹤0.01% | 5480 |
|
|
2015
Q4 | $647K | Buy |
+19,591
| New | +$638K | ﹤0.01% | 4690 |
|
|
2015
Q3 | – | Sell |
-31,059
| Closed | -$1.4M | – | 7328 |
|
|
2015
Q2 | $1.4M | Sell |
31,059
-13,438
| -30% | -$523K | ﹤0.01% | 4211 |
|
|
2015
Q1 | $1.36M | Sell |
44,497
-90,534
| -67% | -$3.52M | ﹤0.01% | 4164 |
|
|
2014
Q4 | $6.87M | Buy |
135,031
+87,564
| +184% | +$3.92M | ﹤0.01% | 2683 |
|
|
2014
Q3 | $1.88M | Buy |
47,467
+42,468
| +850% | +$1.69M | ﹤0.01% | 3997 |
|
|
2014
Q2 | $215K | Buy |
+4,999
| New | +$191K | ﹤0.01% | 6152 |
|
|
2014
Q1 | – | Sell |
-9,541
| Closed | -$260K | – | 6798 |
|
|
2013
Q4 | $260K | Sell |
9,541
-40
| -0.4% | -$969 | ﹤0.01% | 5794 |
|
|
2013
Q3 | $220K | Sell |
9,581
-4,093
| -30% | -$78.2K | ﹤0.01% | 5794 |
|
|
2013
Q2 | $242K | Buy |
+13,674
| New | +$267K | ﹤0.01% | 5463 |
|
Other funds holding ENTA
FCM
KAM
DTC
VCM
VPM
SSC
Goldman Sachs's ENTA Position: Q1 2026 in Review
Goldman Sachs increased its Enanta Pharmaceuticals (ENTA) stake by 21% in Q1 2026, buying an estimated $620K and bringing the position to 265,088 shares worth $3.35M. The position accounts for ﹤0.01% of the portfolio, ranked #4079.
Goldman Sachs first reported a position in ENTA in Q2 2013 and has held it in 49 quarters since. The position peaked at $20.7M in Q4 2019. 132 funds tracked by Wall St. Rank hold ENTA as of Q1 2026.
- Goldman Sachs held 265,088 shares of Enanta Pharmaceuticals worth $3.35M as of Q1 2026.
- Goldman Sachs bought 46,272 Enanta Pharmaceuticals shares in Q1 2026, an estimated $620K.
- Enanta Pharmaceuticals made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #4079 holding.
- Goldman Sachs first reported a position in Enanta Pharmaceuticals in Q2 2013 and has held it in 49 quarters since.
- Goldman Sachs's Enanta Pharmaceuticals position peaked at $20.7M in Q4 2019.
- 132 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2026.
Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.